Bioline pulled drug trial, stock tumbled 50% Wednesday
Anti-psychotic drug under development proved no better than the standard schizophrenia medication.
Shares of Bioline tumbled 50% on Wednesday after the Israeli biomed company said it is halting Phase Israeli clinical trials of an anti-psychotic drug.
register with haaretz
Like us on Facebook and get articles directly in your news feed